Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.

Internal tandem duplication (ITD) of the fms-like tyrosine kinase 3 ( FLT3 ) gene in acute myeloid leukemia (AML) confers an inferior prognosis.[1][1],[2][2] Multi-kinase inhibitors against FLT3 , including midostaurin, sorafenib and quizartinib, have been evaluated either as single agents or in